French biotech firm OSE Pharma has entered into an exclusive long-term agreement with Israel’s privately-held RAFA Laboratories for the registration, marketing, distribution and sales of its investigational lung cancer drug Tedopi. 12 May 2015
India’s Biocon, Asia’s premier biotechnology company, says that it has made clinical progress in its partnered programs with US generics major Mylan. 11 May 2015
The Australian government will invest A$1.3 billion ($1.02 billion) listing new medicines and vaccines that will save lives and help thousands of Australians manage debilitating conditions in its 2015-16 Budget. 9 May 2015
Swiss pharma major Roche and US drugmaker AbbVie have been granted Breakthrough Therapy designation by the US Food and Drug Administration for their investigational medicine venetoclax. 8 May 2015
Japan’s largest drugmaker Takeda Pharmaceutical and the National Cancer Center of Japan have signed an agreement with the goal to discover and develop superior, innovative anti-cancer agents originated in Japan. 8 May 2015
Plexxikon has entered into a collaboration with US pharma giant Merck & Co to evaluate the combination of PLX3397 and Keytruda (pembrolizumab). 8 May 2015
Swiss pharma giant Novartis has received European Commission approval for Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. 8 May 2015
The US Court of Appeals for the Federal Circuit issued an injunction this week blocking Swiss pharma major Novartis’ US generics subsidiary Sandoz Inc from selling a biosimilar version of Amgen’s drug Neupogen (filgrastim) 7 May 2015
Clinical-stage biotech company Tiziana has licensed a new anti-cancer stem cell agent, capable of targeting aggressive tumor-forming cells originating from the breast, pancreas, colon and prostate, from Cardiff University scientists. 7 May 2015
Global spending on oncology medicines in 2014 reached $100 billion, up 10.3% over 2013 and up from $75 billion in 2010 according to a new report from the IMS Institute for Healthcare Informatics. 5 May 2015
Sorrento Therapeutics says that its fully-owned subsidiary, Igdrasol, has acquired exclusive distribution rights from South Korea’s Samyang Biopharmaceuticals to Cynviloq (marketed as Genexol-PM in South Korea) in South America. 3 May 2015
US cancer metabolism specialist Agios Pharmaceuticals says it plans to advance into clinical development AG-881, a small molecule that has shown in preclinical studies to fully penetrate the blood brain barrier and inhibit isocitrate dehydrogenase-1 (IDH1) and IDH2 mutant cancer models. 1 May 2015
The global treatment market value for prostate cancer will expand more than threefold from $2.6 billion in 2013 to an estimated $8.2 billion by 2023, according to research and consulting firm GlobalData. 1 May 2015
Northern Biologics, a privately held biotechnology company backed by Versant Ventures, today announced an exclusive, strategic collaboration with Celgene Corp. 29 April 2015
USA-based Amgen’s marketing application for talimogene laherparepvec (T-Vec) currently does not support it being reviewed under an accelerated approval pathway, according to briefing documents prepared by agency staff released ahead of the US Food and Drug Administration’s advisory committee meeting tomorrow. 28 April 2015
Celgene Corp has entered into a definitive agreement to acquire San Francisco-based Quanticel Pharmaceuticals, a privately held biotechnology company focused on cancer drug discovery. 28 April 2015
Swiss drug major Novartis has announced top-line results from the Phase III COMPLEMENT 2 study showing that Arzerra (ofatumumab) plus fludarabine and cyclophosphamide met the primary endpoint of improved progression-free survival in patients with relapsed chronic lymphocytic leukemia (CLL). 28 April 2015
Swiss drug major Roche’s Avastin (bevacizumab) has been authorized in the UK in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. 28 April 2015
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024